
Danaher Corp, with its ticker symbol DHR, is a multinational conglomerate with a diverse portfolio of businesses. It operates in various industries, including life sciences, diagnostics, and environmental technologies.
The company's financial performance has been impressive, with a revenue growth rate of 5-7% over the past few years. This growth is largely driven by its strategic acquisitions and investments in emerging markets.
Danaher's financial analysis reveals a strong cash position, with a cash balance of over $10 billion as of the latest quarter. This cash reserve provides the company with flexibility to pursue future growth opportunities.
The company's revenue mix is also worth noting, with a significant portion coming from its life sciences and diagnostics segment. This segment has been a key driver of Danaher's growth, with revenue increasing by 10% in the latest quarter.
For more insights, see: Orbital Sciences Corporation
Broaden your view: What Is a Shell Company
Financial Performance
Danaher Corp's (DHR) financial performance is a mixed bag. The company's trailing total returns as of 9/26/2025, which may include dividends or other distributions, are worth noting.
The company's profitability is a key area of interest. With a profit margin of 14.21%, Danaher Corp is generating significant profits from its operations. Its return on assets (ROA) is a respectable 4.01%, indicating that the company is using its assets efficiently to generate revenue.
Danaher Corp's revenue has been holding steady, with a total revenue of $24.01 billion (ttm). This is a testament to the company's diversified business model and its ability to adapt to changing market conditions.
Here's a summary of Danaher Corp's key financial metrics:
Danaher Corp's financial performance is a complex picture, with both positive and negative trends. However, with a solid profitability and revenue growth, the company is well-positioned for future success.
Broaden your view: B P C L Share
Performance Overview
The performance of a company is a crucial aspect of its overall health. As of 9/26/2025, the trailing total returns of DHR, which may include dividends or other distributions, are a key indicator of its performance.
Benchmarking against the S&P 500 (^GSPC) is a common practice to gauge a company's performance relative to the market. This helps investors understand how DHR is faring compared to other companies in the industry.
To get a better understanding of DHR's performance, let's take a look at some key metrics. Here are some of the most relevant ones:
These metrics provide a snapshot of DHR's profitability and efficiency in using its assets and equity to generate revenue. A higher profit margin, for example, indicates that DHR is able to retain a larger percentage of its revenue as profit.
Now, let's examine DHR's revenue and net income over the past year. Total revenue held flat since last year, but increased 3.4% since last quarter. Net income, on the other hand, decreased 18.16% since last year and 41.82% since last quarter.
EPS decreased 17.14% since last year and 41.68% since last quarter. This indicates a decline in DHR's earnings per share over the past year and quarter.
In terms of cash flow, DHR's total cash is $2.96B, and its levered free cash flow is $3.88B. The company's debt-to-equity ratio is 35.45%, indicating a moderate level of debt relative to its equity.
Consider reading: Dhr Fmla
Forecasts
The company is expected to return to its long-term growth rate. This is a promising sign for investors and stakeholders.
The biotechnology, diagnostics, and life sciences company has been performing well in recent times, suggesting a strong foundation for future growth.
Stocks Down Monday
Shares of Danaher are down Monday due to the spinoff of its environmental and applied solutions segment into a new company, Veralto.
The company's guidance is getting complicated, which is likely contributing to the decline in stock value.
Danaher's recent spinoff is a significant event, marking a major change in the company's structure.
The spinoff of Veralto is a strategic move, but it's unclear how it will impact the company's overall performance.
Investors are likely reevaluating their expectations for Danaher's future growth and profitability.
Financial Analysis
Danaher Corp (DHR) has a total cash of $2.96 billion as of the most recent quarter. This is a significant amount of liquidity that can be used to fund operations, pay off debt, or invest in growth initiatives.
The company's debt-to-equity ratio is a bit high at 35.45%, indicating that Danaher Corp relies heavily on debt to finance its operations. This can be a concern for investors, as high debt levels can increase the risk of default.
Danaher Corp's levered free cash flow is a healthy $3.88 billion as of the trailing 12 months. This suggests that the company has a strong ability to generate cash from its operations, which can be used to pay off debt, invest in growth initiatives, or return value to shareholders.
The biotechnology, diagnostics, and life sciences company looks set to return to its long-term growth rate, according to recent news and analysis. This is a positive sign for investors, as it suggests that the company's growth prospects are improving.
Danaher Corp's profitability metrics are impressive, with a profit margin of 14.21% and a return on assets (ROA) of 4.01%. This indicates that the company is able to generate significant profits from its operations, even after accounting for expenses and other factors.
Here are some key profitability metrics for Danaher Corp, as well as its peers:
Danaher Corp's revenue has held flat since last year, but has increased 3.4% since last quarter. This suggests that the company's revenue growth is slowing, but is still positive.
For another approach, see: Bose Corporation Revenue
News and Updates
Danaher Corp (DHR) is looking up. The biotechnology, diagnostics, and life sciences company is on track to return to its long-term growth rate.
This is a significant development for investors, as Danaher Corp has been a reliable performer in the market.
Frequently Asked Questions
What kind of company is DHR?
Danaher Corporation (DHR) is a multinational conglomerate that specializes in designing and manufacturing medical, research, and industrial products and services. It operates in three main segments: Biotechnology, Life Sciences, and Diagnostics.
Featured Images: pexels.com


